Evaluating the Effect of Cromolyn Sodium in Uremic Pruritus
Launched by SHIRAZ UNIVERSITY OF MEDICAL SCIENCES · Sep 2, 2008
Trial Information
Current as of April 29, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Hemodialysis patients \> 18 yo suffering from pruritus for at least 6 weeks, and who have not responded to other drugs
- • Willing and able to give informed concent
- Exclusion Criteria:
- • Known dermatologic, liver, metabolic disease, or any other disease or condition other than ESRD that causes pruritus
- • Lactase deficiency
About Shiraz University Of Medical Sciences
Shiraz University of Medical Sciences (SUMS) is a leading academic institution in Iran dedicated to advancing healthcare through innovative research and education. As a prominent clinical trial sponsor, SUMS plays a pivotal role in conducting rigorous clinical studies aimed at improving medical practices and patient outcomes. The university is committed to fostering collaboration among healthcare professionals, researchers, and industry partners to translate scientific discoveries into effective therapies. With a focus on ethical standards and regulatory compliance, SUMS strives to contribute to the global body of medical knowledge while enhancing the quality of care within the community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shiraz, Fars, Iran, Islamic Republic Of
Patients applied
Trial Officials
Ghazal Vessal, PharmD, BCPS
Study Director
Shiraz University of Medical Sciences
Mohammad Mahdi Sagheb, MD
Principal Investigator
Shiraz University of Medical Sciences
Saman Shilian, Pharm student
Principal Investigator
Shiraz University of Medical Sciences
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials